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Hepatoblastoma: 15-year experience and role of 
surgical treatment
Suk-Bae Moon, Hyun-Baek Shin, Jeong-Meen Seo, Suk-Koo Lee
Division of Pediatric Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 
Seoul, Korea
Purpose: Hepatoblastoma is the most common malignant liver tumor in children. The aim of this study was to review our re-
sults of hepatoblastoma treatment and to determine the role of surgical treatment in hepatoblastoma. Methods: This is a ret-
rospective clinical study. The medical records of patients with hepatoblastoma, treated between October 1994 and October 
2009, were reviewed. The patients were classified according to the pretreatment extent of disease (PRETEXT) grouping 
system. The main outcome variable was survival. Secondary outcome variables were complete, partial and no response to 
chemotherapy and surgery, when indicated. Results: Twenty-seven patients were treated during the observation period. 
Eighteen were males. Five were PRETEXT group I, 8 group II, 13 group III and 1 group IV. Complete excision was achieved in 
all patients except in one case that underwent liver transplantation (group IV). Median follow-up and survival rate were 2.3 
years and 100%, 6.6 years and 75%, 5.8 years and 92%, 7.7 years and 100%, for groups I to IV, respectively. Twenty patients are 
currently considered to be in complete response status and three patients are receiving postoperative chemotherapy. Four 
patients died; the causes of death were cytomegalovirus hepatitis, bone marrow suppression during adjuvant chemotherapy, 
primarynonfunction after the transplantation for recurrent tumor and metachronous rectal cancer, respectively. Conclusion: 
Favorable long-term outcome could be expected for hepatoblastoma with complete tumor excision and adjuvant 
chemotherapy.
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INTRODUCTION
Hepatoblastoma is the most common malignant liver 
tumor and the third most common intra-abdominal neo-
plasm in children. The survival of patients with a hepato-
blastoma has markedly improved in recent years with the 
advances in chemotherapy and surgery. Several national 
and international cooperative studies have shown that the 
prognosis for hepatoblastoma can be improved dramati-
cally by combining surgery with pre- and post-operative 
chemotherapeutic agents such as cisplatin and adriamy-
cin [1,2]. Complete resection is the primary goal of surgical 
treatment and a prerequisite for cure, and effective neo-
adjuvant chemotherapy is important for complete re-Hepatoblastoma and surgical treatment
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section [3]. Recently, liver transplantation has been consid-
ered as an alternative option in cases with unresectable tu-
mors and favorable outcomes have been reported [4]. The 
5-year survival rate of hepatoblastoma has improved from 
35% three decades ago to 75% in some recent series [5,6]. 
The aim of this study was to review our experience with 
the treatment of patients with hepatoblastoma and to de-
termine the role of surgery in hepatoblastoma treatment. 
METHODS
Patients
The medical records of 27 patients, treated at the 
Department of Surgery and Department of Pediatrics, 
Samsung Medical Center, between October 1994 and 
October 2009, were reviewed. The clinical, radiological, 
and surgical data were obtained. Tumor extension was as-
sessed by computed tomography (CT) and by chest X-ray 
and CT for pulmonary lesions. Biopsy of the tumor was 
mandatory except in cases where the tumor seemed read-
ily resectable. Tumor stage was established with the pre-
treatment extent of disease (PRETEXT) system, based on 
the radiological findings. As the PRETEXT system was de-
veloped at 2005 and we applied the system since then, pa-
tients who were treated before 2005 were classified 
retrospectively. High-risk patients were defined accord-
ing to the previous study protocol [7].
Treatment
Patients were initially assessed for the tumor resec-
tability. When the tumor was readily resectable (PRETEXT 
I), partial hepatectomy was attempted without pre-
operative chemotherapy. In contrast, for PRETEXT II and 
III tumors, neo-adjuvant chemotherapy was administered 
in an attempt to enable safe and complete resection. After 
histological diagnosis with a percutaneous biopsy, pre-
operative chemotherapy was administered with cisplatin, 
90 mg/m
2 × 1 day and adriamycin, 20 mg/m
2 × 4 days. 
These courses were repeated every 4 weeks and the pa-
tients were re-assessed for the tumor resectability after 4 
courses. If the tumor was deemed resectable, patients were 
referred to one of our authors (LSK) for complete resec-
tion. If deemed unresectable, patients were treated with 
another 2 courses followed by re-evaluation for resection. 
The liver transplantation was planned for patients 
deemed unresectable at this point. Regardless of the re-
sectability, a maximum of 6 courses were given pre-
operatively. Standard anatomical resection was attemp-
ted, and clear resection margins were confirmed during 
the operation. Metastatic lesions that persisted after the 
preoperative chemotherapy were removed surgically, if 
possible. Complete resection was defined as no residual 
tumor by macroscopic or microscopic findings. All pa-
tients underwent postoperative chemotherapy with the 
same regimen, which was repeated up to a total of six 
courses until the serum α-fetoprotein (AFP) returned to 
the normal range. 
Evaluation of treatment response
Assessment of response to the treatment was performed 
with AFP and CT after completion of the required 
treatment. The definitions used were as follow: complete 
response (CR) was no evidence of disease after complete 
resection and normal AFP; partial response (PR) was any 
tumor size decrease associated with decreased AFP (＞1 
log less than the original value); stable disease (SD) was no 
tumor size change and no change or less than 1 log de-
crease of AFP; and progressive disease (PD) was un-
equivocal increase in size of the tumor and/or any un-
equivocal increase of AFP.
Outcome measure
The main outcome measure was overall and event-free 
survival. Secondary outcome measures included CR, PR, 
SD, and PD. An event was defined as the disease-related 
patient death or disease relapse. Survival time was defined 
as the time from the diagnosis to the event.
RESULTS
Clinical features of the 27 patients with hepato-
blastoma (Table 1)
The median age at the time of the diagnosis was 18 
months (range, 2 months to 12.6 years), and the gender dis-Suk-Bae Moon, et al.
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Clinical features Value
Age, median (range) 18 mo (2 mo-12.6 yr)
Sex (M:F) 18:9 
Location
   Right
   Left





   I   5 
   II   8 
   III 13
   IV   1 
Metastasis 2 (lung)
Associated conditions
   BW syndrome
   FAP




No. of high-risk patients    5
a)
Serum AFP (ng/mL), median (range) 71,820 (1-426,332)
Surgical treatment
   Resection 26
   Transplantation     2
b)
Pre-operative chemotherapy 20 
Post-operative chemotherapy 26 
Histology, n (%)
   Epithelial, pure fetal   7 (25.9)
   Epithelical, fetal/embryonal 12 (44.4)
   Mixed   8 (29.7)
PRETEXT, pretreatment extent of disease; BW, Beckwith- Wie-
demann; FAP, familial adenomatous polyposis; CMV, cytome-
galovirus; AFP, α-fetoprotein. 
a)Distant metastasis (n = 2), PRETEXT IV (n = 1), low serum AFP (n 
= 1), tumor rupture at presentation (n = 1). 
b)One patient under-
went living-related liver transplantation for the recurrent tumor 
after post-operative chemotherapy.
Table 1. Clinical features of 27 hepatoblastoma patients
tribution was 18:9 (male:female). The tumor was located at 
the right hemiliver in 21 patients, left hemiliver in 5 pa-
tients, and throughout the whole liver in 1 patient. After 
PRETEXT classification, group I included 5 patients, 
group II 8 patients, group III 13 patients, and group IV 1 
patient. Two patients had synchronous lung metastasis at 
the time of diagnosis (PRETEXT group II [multiple meta-
stases] and III [solitary metastasis]). Associated conditions 
were as follow: Beckwith-Wiedemann syndrome (n = 2), 
familial adenomatous polyposis (FAP; n = 1), and cytome-
galovirus (CMV) hepatitis (n = 1). Age-adjusted serum 
AFP levels were elevated in 26 patients except 1 patient 
(PRETEXT I, 1 ng/mL), with a median level of 71,820 
ng/mL (range, 1 to 426,332 ng/mL). Twenty patients had 
preoperative chemotherapy, and postoperative chemo-
therapy was administered in 26 patients. For surgical 
treatment, complete tumor resection was achieved in 26 
patients and 1 patient underwent primary living-related 
liver transplantation.
Surgical and pathological results
Six patients underwent complete surgical excision as 
primary therapy without preoperative chemotherapy: 
five patients in group I for readily resectable tumors (3 sec-
tionectomies, 2 right hemihepatectomies) and one patient 
in group II for a ruptured tumor (emergency surgery, right 
hemihepatectomy). One patient (group IV) underwent 
primary liver transplantation for bilateral multiple hep-
atoblastomas, which was initially misdiagnosed as hep-
atocellular carcinoma after percutaneous biopsy. For the 
remaining 20 patients (7 group II patients and 13 group III 
patients), preoperative chemotherapy was administered 
and complete tumor excision was achieved thereafter. 
There were 6 hemihepatectomies and 1 sectionectomy in 
group II patients, and 4 trisectioinectomies, 7 hemi-
hepatectomies, 2 sectionectomies in group III patients. In 
group III, seven unresectable cases were rendered resect-
able after preoperative chemotherapy (Fig. 1). Postoper-
ative chemotherapy was administered in all patients re-
gardless of the PRETEXT classification except in the one 
patient who underwent primary liver transplantation. The 
pathological results and the treatment courses are sum-
marized in Table 1 and Table 2, respectively. 
Treatment outcome according to the PRETEXT 
classification (Table 2)
The median follow-up duration was 6.5 years (range, 3 
months to 15 years) after the diagnosis. Twenty patients 
have a CR status, three patients are receiving post-
operative chemotherapy, and four patients died. Two pa-
tients, in group II, died of medical complications post-
operatively. In one patient, although biochemical liver 
function test was abnormal preoperatively, CMV hepatitis 
was not suspected and no evaluation on viral hepatitis 
other than hepatitis B was performed. Pathological exami-
nation revealed the CMV infection on operative specimen, Hepatoblastoma and surgical treatment
thesurgery.or.kr 137
Fig. 1. (A) Tumor involved three adjacent sections (arrow) and complete resection with safe margins seems unlikely. (B) After 6 courses of 
neoadjuvant chemotherapy, extent of tumor decreased markedly (arrowhead) and was treated successfully with right hemihepatectomy.
PRETEXT Treatment course Outcome 5-yr EFS (%)
I (n = 5) Hepatectomy →  CTx (n = 5) 3 CR, 2 PR
c) 100.0
II (n = 8) Hepatectomy →  CTx (n = 1)
a)
CTx →  hepatectomy →  CTx (n = 7)
6 CR, 2 died
d)  75.0
III (n = 13) CTx →  hepatectomy →  CTx (n = 13)
b) 10 CR, 1 PR
c), 2 died
e)  91.6
IV (n = 1) Primary transplantation (living-related) CR 100.0
PRETEXT, pretreatment extent of disease; EFS, event-free survival; CTx, chemotherapy; CR, complete response; PR, partial response.
a)This patient underwent emergency operation for the ruptured tumor. 
b)One patient underwent living-related liver transplantation for the 
recurrent tumor after partial hepatectomy. 
c)These patients are currently under postoperative chemotherapy. 
d)The cause of death was CMV 
hepatitis and bone marrow suppression during the postoperative CTx, respectively. 
e)The cause of death was metachronous rectal cancer 
and primary nonfunction after liver transplantation, respectively.
Table 2. Treatment course and outcome according to the PRETEXT classification
Fig. 2. The event-free survival according to the PRETEXT 
classification.
which was not evident on preoperative biopsy. Postoper-
ative ganciclovir treatment failed to recover the liver func-
tion and the patient died of hepatic failure 8 months after 
the operation. The other patient showed persistent pan-
cytopenia after completion of 3 courses of postoperative 
chemotherapy. The patient recovered well from the pre-
ceding 2 courses of chemotherapy. Bone marrow examina-
tion revealed the myelodysplastic syndrome, and the pa-
tient died of sepsis and multi-organ failure 2 months after 
the diagnosis of myelodysplastic syndrome. One patient, 
who was in group III, died of rectal cancer with multiple 
lung and liver metastases 15 years after the diagnosis of 
hepatoblastoma. In this case, numerous polyps were not-
ed throughout the whole colon and rectum; there was no 
family history of colorectal cancer, but the adenomatous pol-Suk-Bae Moon, et al.
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yposis coli (APC) gene mutation test was positive and the 
sporadic FAP was confirmed. One patient, who was also in 
group III, showed intrahepatic relapse 11 months after 
hepatectomy and was treated with a living-related liver 
transplantation; however, the patient  died of primary 
non-function eight days after the transplantation. Both of 
the patients with initial lung metastases currently have a 
CR status. The overall 5-year event-free survival (EFS) was 
87.8%, while 5-year EFS by PRETEXT grouping was 100%, 
75%, 92% and 100% for group I to IV, respectively (Fig. 2). 
DISCUSSION
The goal of this study was to review our experience with 
the treatment of hepatoblastoma and to determine the role 
of surgical treatment in hepatoblastoma. The pre- or 
post-operative chemotherapy protocol using a combina-
tion of cisplatin and adriamycin has been the standard 
treatment for hepatoblastoma in Japan since 1991 
(Japanese Study Group for Pediatric Liver Tumors Proto-
col-1 [JPLT-1]); the results of the JPLT-1 trial were similar 
to those from Europe and United States [8]. However, the 
Japanese trial used staging criteria somewhat different 
from those of the PRETEXT classification, and therefore a 
direct comparison with our results cannot be made. Suita 
et al. [9] recently published the findings of improved sur-
vival with the JPLT-1 protocol with results similar to this 
s t u d y .  T h e y  c o n c l u d e d  t h a t  the combination of cispla-
tin-adriamycin could improve survival by increasing the 
resectability of the tumor or by improving the cure rate in 
cases with incomplete tumor resection. In this study, most 
of the patients in group III benefitted from neoadjuvant 
chemotherapy with a similar regimen and could achieve 
complete tumor resection, thus showing the usefulness of 
the regimen as a preoperative treatment. However, as 
there were no cases with an incomplete resection in this 
study, the benefit of this regimen on residual tumor could 
not be evaluated. 
The survival of patients with hepatoblastoma is usually 
correlated with the PRETEXT classification; group I being 
the best and group IV the worst [9,10]. By contrast, our re-
sults showed the worst survival in group II and the best 
survival in groups I and IV. We speculate that this is prob-
ably due to low patient number. Moreover, the causes of 
death in the group II patients might have been prevented 
by different medical management; although the post-che-
motherapy myelodysplastic syndrome was difficult to 
predict and fatal if affected, CMV hepatitis could have 
been treated preoperatively by careful patient evaluation 
and the patient death would have been prevented. 
Therefore, the survival of group II patients might have 
been similar or even better than group III with different 
medical intervention. Most recently published paper 
showed the improved survival in PRETEXT IV patients 
with dose-intensive chemotherapy and surgery [7], and 
similar results were obtained with total hepatectomy and 
liver transplantation [11]. In our study, only one case in 
group IV was successfully treated with a liver trans-
plantation and the chemotherapeutic regimen was 
different. Therefore, the comparison of the survival would 
seem inappropriate, but we expect long-term disease-free 
survival in this patient.
Transplantation after tumor recurrence, the so called 
“rescue transplantation”, has a much worse survival rate 
compared to primary transplantation [11,12]. Some inves-
tigators have suggested that recurrence of a tumor after a 
primary resection is a relative contraindication to trans-
plantation [13]. Although this series had only two cases of 
transplantation (one primary and one rescue) for hepato-
blastoma, our experience is consistent with previously re-
ported results. Most of the causes of death after rescue 
transplantation have been related to the recurrence of dis-
ease within the first year after the transplantation. The pa-
tient who underwent rescue transplantation in this study, 
however, died of primary nonfunction after rescue trans-
plantation. This might be explained in part by the anasto-
mosis between the portal vein of the liver graft and the re-
cipient renal vein, which showed insufficient blood flow; 
the patient had portal vein thrombosis. 
Adjuvant chemotherapy after primary transplantation 
has been the subject of debate. Many investigators have 
recommended posttransplantation chemotherapy when-
ever possible for reducing the frequency of tumor re-
currence and improving the rate of survival [14]. Howev-
er, the risk of chemotherapy must be balanced between the Hepatoblastoma and surgical treatment
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posttransplantion complication and the risk of immunos-
uppression. Although only one patient was cured by 
transplantation without adjuvant chemotherapy, consid-
ering the risk of disease relapse in the transplanted liver, 
posttransplantation chemotherapy should be considered 
for prevention in similar cases.
FAP is a well-known autosomal dominant cancer pre-
disposition syndrome caused by germline mutations in 
the tumor suppression gene APC. Since first described in 
1982, the association of FAP with hepatoblastoma has 
steadily been reported and the estimated risk of hepato-
blastoma is 750 to 7500 times higher in children predis-
posed to FAP than in the general population [15]. Con-
versely, however, the frequency of FAP in cases of hepato-
blastoma without a family history of FAP is unknown. 
Phillips et al. [16] reported only one case of FAP in 20 (5%) 
patients with hepatoblastoma and Aretz et al.[15] found 
APC germline mutations in five patients after screening of 
50 patients (10%) with apparently sporadic hepatobla-
stoma. Some investigators have suggested routine germ-
line mutation screening of the APC gene in every child 
with hepatoblastoma [17]. Although we have not rou-
tinely performed APC mutation testing in patients with 
hepatoblastoma, it might be appropriate to perform APC 
mutation testing at the time of the diagnosis of a hepato-
blastoma.
In summary, favorable survival outcome could be ach-
ieved with complete tumor excision and adjuvant chemo-
therapy. For initially unresectable tumor, neoadjuvant 
chemotherapy based on the combination of cisplatin- 
adriamycin was effective for tumor down-sizing and im-
proving the resectability in group II and III patients. The 
APC mutation should be ruled out in all hepatoblastoma 
patients. 
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article 
was reported.
REFERENCES
1. Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, 
Brock P, et al. Pretreatment prognostic factors for children 
with hepatoblastoma: results from the International 
Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur 
J Cancer 2000;36:1418-25.
2. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicks-
man A. Cisplatin, vincristine, and fluorouracil therapy for 
hepatoblastoma: a Pediatric Oncology Group study. J Clin 
Oncol 1993;11:96-9.
3. Atkinson JB, DeUgarte DA. Liver tumors. In: Grosfeld JL, 
O’Neill JA, Fonkalsrud EW, Coran AG, editors. Pediatric 
surgery. 6th ed. Philadelphia: Mosby; 2006. p.502-14.
4. Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, 
Maibach R, et al. Liver transplantation for hepatoblastoma: 
results from the International Society of Pediatric 
Oncology (SIOP) study SIOPEL-1 and review of the world 
experience. Pediatr Blood Cancer 2004;42:74-83.
5. Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, 
Dicks-Mireaux C, et al. Cisplatin, doxorubicin, and de-
layed surgery for childhood hepatoblastoma: a successful 
approach: results of the first prospective study of the 
International Society of Pediatric Oncology. J Clin Oncol 
2000;18:3819-28.
6. Aronson DC, Schnater JM, Staalman CR, Weverling GJ, 
Plaschkes J, Perilongo G, et al. Predictive value of the pre-
treatment extent of disease system in hepatoblastoma: re-
sults from the International Society of Pediatric Oncology 
Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 
2005;23:1245-52.
7. Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, 
Czauderna P, et al. Successful treatment of childhood 
high-risk hepatoblastoma with dose-intensive multiagent 
chemotherapy and surgery: final results of the SIOPEL- 
3HR study. J Clin Oncol 2010;28:2584-90.
8. Sasaki F, Matsunaga T, Iwafuchi M, Hayashi Y, Ohkawa H, 
Ohira M, et al. Outcome of hepatoblastoma treated with 
the JPLT-1 (Japanese Study Group for Pediatric Liver 
Tumor) Protocol-1: a report from the Japanese Study 
Group for Pediatric Liver Tumor. J Pediatr Surg 2002;37: 
851-6.
9 . S u i t a  S ,  T a j i r i  T ,  T a k a m a t s u  H ,  M i z o t e  H ,  N a g a s a k i  A ,  
Inomata Y, et al. Improved survival outcome for hepato-
blastoma based on an optimal chemotherapeutic regimen: 
a report from the study group for pediatric solid malignant 
tumors in the Kyushu area. J Pediatr Surg 2004;39:195-8.
10. Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein 
HM, Malogolowkin MH. Predictive power of pretreatment 
prognostic factors in children with hepatoblastoma: a re-
port from the Children's Oncology Group. Pediatr Blood 
Cancer 2009;53:1016-22.
11. Otte JB. Progress in the surgical treatment of malignant liv-
er tumors in children. Cancer Treat Rev 2010;36:360-71.
12. Browne M, Sher D, Grant D, Deluca E, Alonso E, Whiting-
ton PF, et al. Survival after liver transplantation for hepato-
blastoma: a 2-center experience. J Pediatr Surg 2008;43: Suk-Bae Moon, et al.
140 thesurgery.or.kr
1973-81.
13. Cillo U, Ciarleglio FA, Bassanello M, Brolese A, Vitale A, 
Boccagni P, et al. Liver transplantation for the management 
of hepatoblastoma. Transplant Proc 2003;35:2983-5.
14. Srinivasan P, McCall J, Pritchard J, Dhawan A, Baker A, 
Vergani GM, et al. Orthotopic liver transplantation for un-
resectable hepatoblastoma. Transplantation 2002;74:652-5.
15 . Aretz  S, Koch A, Uhlhaas S, F riedl W , Propping P , v on 
Schweinitz D, et al. Should children at risk for familial ad-
enomatous polyposis be screened for hepatoblastoma and 
children with apparently sporadic hepatoblastoma be 
screened for APC germline mutations? Pediatr Blood 
Cancer 2006;47:811-8.
16. Phillips M, Dicks-Mireaux C, Kingston J, Malone M, 
Mitchell C, Pritchard J, et al. Hepatoblastoma and poly-
posis coli (familial adenomatous polyposis). Med Pediatr 
Oncol 1989;17:441-7.
17. Thomas D, Pritchard J, Davidson R, McKiernan P, Grundy 
RG, de Ville de Goyet J. Familial hepatoblastoma and APC 
gene mutations: renewed call for molecular research. Eur J 
Cancer 2003;39:2200-4.